Genzyme submits applications to FDA and EMA for approval of LEMTRADA™ (alemtuzumab) for multiple sclerosis
12 June 2012 | By Sanofi
Genzyme is developing LEMTRADA in MS in collaboration with Bayer HealthCare...
List view / Grid view
12 June 2012 | By Sanofi
Genzyme is developing LEMTRADA in MS in collaboration with Bayer HealthCare...
11 June 2012 | By Sanofi
New results of a large-scale epidemiological program announced...
11 June 2012 | By GlaxoSmithKline
Stiefel has entered into a worldwide agreement to acquire Toctino (alitretinoin) from Basilea Pharmaceutica Ltd...
11 June 2012 | By Catalent Pharma Solutions
Michael Valazza, to conduct a workshop on “Coordination of Activities and Responsibilities for Solid Dosage Forms”...
11 June 2012 | By Daiichi Sankyo
Daiichi Sankyo Group’s leading antihypertensive franchise olmesartan medoxomil launched...
11 June 2012 | By Sanofi
Sanofi announced that the marketing authorization application for Lyxumia®...
11 June 2012 | By Novo Nordisk
New data show that Victoza® provided greater reductions in HbA1c...
Eli Lilly and Company and Incyte Corporation announced the presentation of 12-week results from a Phase IIb study of baricitinib, formerly LY3009104 (INCB28050), an orally available janus kinase (JAK) inhibitor, in patients with active rheumatoid arthritis (RA).
11 June 2012 | By Roche
Roche announced that the U.S. FDA has approved PerjetaTM (pertuzumab)...
11 June 2012 | By Novartis
New long-term data for Gilenya®...
11 June 2012 | By Boehringer Ingelheim
Eli Lilly and Company and Boehringer Ingelheim announced results from two Phase II studies...
9 June 2012 | By GlaxoSmithKline
Detailed 52 and 32-week data from the first two Phase III studies...
9 June 2012 | By AstraZeneca
AstraZeneca and Bristol-Myers Squibb Company announced results from a Phase 3 clinical study...
8 June 2012 | By GlaxoSmithKline
GSK has extended its tender offer to acquire all of the outstanding shares of HGS...
8 June 2012 | By Amgen
Amgen announced top-line results of the Phase 3 EVOLVE(TM) trial...